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Abstract: High-density lipoproteins (HDLs) play an important role in reverse cholesterol transport
and present antioxidant properties, among others. In the central nervous system (CNS), there are
HDLs, where these lipoproteins could influence brain health. Owing to the new evidence of HDL
functionality remodeling in obese patients, and the fact that obesity-associated metabolic disturbances
is pro-inflammatory and pro-oxidant, the aim of this study was to investigate if HDL functions are
depleted in obese patients and obesity-associated microenvironment. HDLs were isolated from
normal-weight healthy (nwHDL) and obese men (obHDL). The oxHDL level was measured by
malondialdehyde and 4-hydroxynoneal peroxided products. BV2 microglial cells were exposed to
different concentrations of nwHDL and obHDL in different obesity-associated pro-inflammatory
microenvironments. Our results showed that hyperleptinemia increased oxHDL levels. In addition,
nwHDLs reduced pro-inflammatory cytokines’ release and M1 marker gene expression in BV2
microglial cells. Nevertheless, both nwHDL co-administered with LPS+leptin and obHDL promoted
BV2 microglial activation and a higher pro-inflammatory cytokine production, thus confirming that
obesity-associated metabolic disturbances reverse the antioxidant and anti-inflammatory properties
of HDLs in microglial cells.
Keywords: obesity; paraoxonase; lipoproteins; oxidation; microglia; neuroinflammation
1. Introduction
High-density lipoproteins (HDLs) are circulating particles; beyond serving as lipid
transporters, they carry out a wide number of biological functions [1]. The fundamental
activity of HDLs is cholesterol transport from peripheral tissues to the liver for catabolism
and excretion into the bile. Moreover, in physiological conditions, HDLs have been recently
reported to exert other functions, including anti-inflammatory and antioxidant capacity,
highly dependent on HDL composition [2]. The antioxidant capacity of HDLs is mainly
conferred by the presence of apolipoproteins and enzymes transported by HDLs, including
paraoxonase 1 (PON1) [3]. In addition, lipid components are essential in HDL-related
antioxidant capacity in order to prevent their own oxidation and low-density lipoproteins
(LDLs) oxidation [4]. It should be noted that oxidative modifications of HDLs participate in
the impairment of HDL functionality [5]. Indeed, the oxidation of HDLs occurs in different
pathological conditions characterized by an oxidant microenvironment increased, such as
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obesity, diabetes, inflammatory, or renal diseases [6–9]. HDLs isolated from patients with
pathological conditions were shown to have a reduced antioxidant capacity [10–12].
Obesity is known to be associated with circulating hyperleptinemia. Leptin is a
circulating hormone with cytokine-like actions mainly produced by adipose tissue. In
epidemiological studies, a direct correlation of plasma leptin levels with body fat mass
has been described [13]. The most prominent effect of leptin is appetite control, but it has
become increasingly clear that leptin also influences the immune system [14]. As part of its
immune-modulating actions, leptin is able to increase oxidative stress and activation of
monocytes [15] and T cells [16] and mediates homeostasis in a variety of immune cells [17].
In the central nervous system (CNS), leptin activates ObRb in microglial cells and induces
interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α production [18].
Microglia-mediated neuroinflammation is considered to play an important role in the
pathogenesis and progression of neurodegenerative diseases [19]. Similar to periphery
macrophages, it is well-known that microglia can alter their phenotypes and functions
in response to microenvironmental disturbances. Therefore, different stimuli, such as
lipopolysaccharide (LPS), are used to model neuroinflammation associated with neurode-
generation. By acting at its receptors, LPS activates various intracellular molecules, which
alter the expression of a plethora of inflammatory mediators [20]. Depending on the
predominance of secreted factors, microglia have been characterized to express the classi-
cal activation phenotype (M1, pro-inflammatory) or the alternative activation phenotype
(M2, anti-inflammatory) [21]. The M1 state causes the release of proinflammatory and
pro-oxidant mediators with increased expression of CD80 and iNOS. The M2 state is as-
sociated with the expression of the anti-inflammatory and antioxidant mediators, as well
as CD200R and arginase-1 (Arg1) [22,23]. Alterations in microglia M1/M2 polarization
have been associated with neurodegenerative diseases [24,25]. Neuropathologies triggered
by metabolic syndrome, which includes diabetes and obesity, often result from increased
permeability of the blood–brain barrier (BBB), rising the entry of toxins, immune cells,
pathogens, and molecules, as lipoproteins, into the brain [26]. In obesity, HDLs can cross
the BBB and perform the same functions as in other tissues, reverse cholesterol transport,
and antioxidant and anti-inflammatory activities.
The consequence of oxidation on the protective role of HDL against the leptin-induced
oxidation on microglial cells remain unknown. Taken together, the aim of this study was to
investigate the effects of leptin-induced oxidation on HDL isolated from healthy subjects
and HDL isolated from obese individuals with hyperleptinemia on microglial cells.
2. Materials and Methods
2.1. Subjects and Ethics
This study was conducted according to Good Clinical Practice Guidelines and in
line with the principles outlined in the Helsinki Declaration of the World Medical As-
sociation. Ethics approval was obtained from the Human Clinical Research and Ethics
Committee of the University Hospital Virgen Macarena (PI00082017), and all subjects gave
written informed consent. This study included 20 normal-weight (body mass index (BMI)
18–24.9 kg/m2 and leptin levels less than 7 ng/mL) and 20 obese (BMI > 30 kg/m2 and lep-
tin levels over than 40 ng/mL) subjects. Inclusion criteria included age from 18 to 45 years
and no known diseases or taking medication for dyslipidemia, diabetes, hypertension, or
any other metabolic disorders. Males were only included in this study, given the known
differences in lipoproteins by sex and timing of menstrual cycle [27].
2.2. Clinical Measurements
Subjects’ weight, height, waist and neck circumference, and body-fat percentage
were measured by trained recruiters. Weight (nearest 0.1 kg), height (nearest 0.1 cm),
and body-fat percentage were measured by using a TANITA Body Composition Analyzer
(ModelBC-545N). Waist circumference was measured exactly midway between the lowest
rib and the peak of the iliac crest. Neck circumference was measured at the midway point
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of the neck to 0.5 cm just below the laryngeal prominence. Measurements of systolic and
diastolic blood pressure (SBP and DBP) were performed with a standard method. BMI
was calculated as weight (kg)/height (m)2. Lifestyle factors (physical activity, alcohol
consumption, and cigarette smoking) were obtained by standardized questionnaires.
2.3. Biochemical Measurements
Fasting venous blood samples were taken at 8:00 after a 12 h overnight fast. Glucose
was immediately measured by using the glucose/oxidase method (Glucose GOD-PAP; Bio-
labo, Madrid, Spain). Insulin was measured by using enzyme-linked immunosorbent assay
(Diagnostic System Laboratories, Webster, TX, USA). Total cholesterol and triglycerides
were determined by enzymatic methods (CHOD-PAP and GPO-PAP, respectively; Roche
Diagnostics, Basel, Switzerland). HDL cholesterol was determined after precipitation with
phosphotungstic acid. LDL cholesterol was measured by using an Advia 2400 Clinical
Chemistry System (Siemens Healthcare Diagnostics, Erlangen, Germany). NEFAs were
measured with an ACS-ACOD assay (Wako Chemicals GmbH, Neuss, Germany). Glycated
hemoglobin (HbA1c) was measured according to the Standard Operating Procedure of the
IFCC Reference, with an automated high-performance liquid chromatographic analyzer
(Bio-Rad, Milan, Italy).
2.4. HDL Isolation and Oxidized HDL Measurement
For HDL isolation, blood was collected into K2EDTA (Becton-Dickinson, San Jose, CA,
USA) tubes, centrifugated (140× g, 10 min at 4 ◦C), and the plasma removed and stored at
−80 ◦C until analyzed. The HDL fraction was isolated from 200 µL of plasma by density
gradient ultracentrifugation (Beckman Optima TLX, TLA 100.2 rotor, Indianapolis, IN,
USA). Sodium bromide (NaBr, Sigma-Aldrich, Madrid, Spain) and potassium bromide
(KBr, Sigma-Aldrich) salt solutions were used to adjust the density of the plasma as follows:
200 µL plasma was mixed with 1.182 g/mL NaBr to increase the density to 1.019 g/mL.
The plasma was then overlaid with KBr salt solution (density 1.019 g/mL) to a final volume
of 1.0 mL and centrifuged (100,000 rpm, 16 ◦C, 2 h). The VLDL (combined with IDL)
fraction (400 µL) was aspirated from the top of the centrifuge tubes. Then, the remaining
mixture was adjusted to a density of 1.063 g/mL, with NaBr and overlaid to 1.0 mL with
1.182 g/mL KBr solution. LDL was isolated by centrifugation (100,000 rpm, 16 ◦C, 3 h) and
aspiration of the top layer (400 µL). The infranatant was adjusted to a density of 1.21 g/mL
by the addition of 1.488 g/mL NaBr, and overlaid to 1.0 mL with 1.21 g/mL KBr solution
and centrifuged (100,000 rpm, 16 ◦C, 15 h). The HDL fraction (400 µL) was then aspirated
carefully from the top of each tube. Prior to HDL functional assessment, the isolated
HDL fractions were dialyzed against phosphate-buffered saline (PBS), in the dark, at 4 ◦C,
with three buffer changes over 24 h to remove salts. The amount of total protein was
assayed in the isolated HDL fraction according to manufacturer′s kit instructions, using
the bicinchoninic acid assay (BCA, Pierce Biotechnology BCA™ Protein Assay Kit, Thermo
Scientific, Waltham, MA, USA). Briefly, the BSA standards and samples (25 µL) were mixed
with working reagent (200 µL) and aliquoted into 96-well plates. The plates were then
incubated at 37 ◦C for 30 min, and the absorbance (at 562 nm) measured. The protein
concentration of each sample was calculated by comparison to a standard calibration curve
(0–1 mg/mL BCA). To evaluate oxidized HDL levels in plasma, Oxiselect Human Oxidized
HDL ELISA Kit (Cell Biolabs, San Diego, CA, USA), an enzyme immunoassay containing
4-hydroxynonenal-(HNE-)HDL standard with a detection sensitivity limit of 2 ng/mL,
was used.
2.5. Paraoxonase-1 Levels and Activity Assay
Serum samples were diluted 1:10 in phosphate buffer containing 2 mmol/L CaCl2
(pH 8). Diluted serum was added to 96-well plates in triplicate, and paraoxon-ethyl
substrate (Sigma, D9286, Madrid, Spain) was added. Absorbance at 405 nm was measured
at 30 s intervals over 20 min. Paraoxonase-1 activity was expressed as IU/L serum. ELISA
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kit (ThermoFisher Scientific, Madrid, Spain) was used to measure serum concentrations of
paraoxonase-1 and results were expressed as ng/mL.
2.6. BV2 Microglial Cell Culture and Treatments
The immortalized murine microglial cell line BV2 was purchased from the Instituto
de la Grasa (Seville, Spain). Cells were routinely cultured in high-glucose Dulbecco′s
modified Eagle′s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and 1% penicillin/streptomycin (P/S). Culture conditions were 5% CO2 at
37 ◦C. Subcultures were made every 3 days, using 0.25% trypsin-EDTA. To maintain cells
in an undifferentiated state, they were passaged before obtaining confluence. Only BV2
microglial cells at culture passages 5 to 10 were used for the experiments. Before the
treatment, BV2 microglial cells were seeded at a density of 5 × 105 cells/mL in 12-well
plates for 24 h in high-glucose DMEM supplemented with 1% heat-inactivated FBS and 1%
P/S. BV2 microglia cells were exposed to LPS (100 ng/mL) for additional 3 h. To assess the
effect of HDL on microglia polarization, BV2 microglial cells were exposed to HDL isolated
from normal-weight men (nwHDL) and HDL isolated from obese men (obHDL) at 250,
500, and 800 µg/mL during 24 h. Recombinant human Leptin (PeproTech, London, UK)
was added at 10 ng/mL to the medium prior to 30 min incubation.
2.7. RNA Isolation and RT-qPCR Analysis
Total RNA was extracted by using TRIsure Reagent (Bioline, London, UK), as in-
structed by the manufacturer. A260/A280 ratio in a NanoDrop ND-1000 Spectrophotometer
(Thermo Scientific) was used to determinate RNA quality. Momentarily, RNA (1 µg) was
subjected to reverse transcription (iScript, Bio-Rad, Madrid, Spain). An amount of 10 ng of
the resulting cDNA was used as a template for real-time PCR amplifications. The mRNA
levels for specific genes were determined in a CFX96 system (Bio-Rad). For each PCR
reaction, cDNA template was added to Brilliant SYBR green QPCR Supermix (Bio-Rad)
containing the primer pairs for either gene or for glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) and hypoxanthine phosphoribosyltransferase 1 (HPRT) as housekeeping
genes (Supplementary Materials Table S1). All amplification reactions were performed in
triplicate, and average threshold cycle (Ct) numbers of the triplicates were used to calculate
the relative mRNA expression of candidate genes. The magnitude of change of mRNA
expression for candidate genes was calculated by using the standard 2−(∆∆Ct) method. All
data were normalized to endogenous reference (GAPDH and HPRT) gene content and
expressed as percentage of controls.
2.8. Statistical Analysis
All values are expressed as arithmetic means ± standard deviations (SD). Data were
evaluated with Graph Pad Prism Version 6.01 software (San Diego, CA, USA). The statistical
significance of any difference in each parameter among the groups was evaluated by one-
way analysis of variance (ANOVA), following a Tukey multiple comparisons test as post
hoc test. Pearson’s r-value was used to analyze the statistical significance of correlation
test. The p-values less than 0.05 were considered to be statistically significant.
3. Results
3.1. Clinical and Biochemical Characteristics of the Study Subjects
Demographic characteristics and clinical and biochemical measurements of the study
participants are presented in Table 1. Participants with obesity had significantly higher BMI,
waist and neck circumferences, and percent body fat relative to normal-weight participants
(all p < 0.001). While other variables, such as systolic and diastolic blood pressure, NEFAs,
total triglycerides and cholesterol, LDL-C, glucose, and HbA1c, appeared to be higher
in participants with obesity than those with a normal weight, these differences were not
statistically significant. Meanwhile, HDL-C was slightly lower in participants with obesity
compared to those with a normal weight (p = 0.111).
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Table 1. General characteristics of study population.
Variables Normal-Weight Obese p-Value
N 20 20
Age (years) 31.2 ± 6.7 38.5 ± 4.3 0.060
Smoking (%) 20 30 0.465
Alcohol consumption (%) 45 50 0.751
Physical activity (hours/week) 2.7 ± 2.5 2.4 ± 1.8 0.161
BMI (kg/m2) 23.2 ± 1.5 31.9 ± 4.1 <0.001
Waist circumference (cm) 85.3 ± 7.0 124.5 ± 16.1 <0.001
Neck circumference (cm) 29.3 ± 0.5 38.4 ± 2.1 <0.001
Percent body fat 27.4 ± 0.4 39.6 ± 1.6 <0.001
Systolic blood pressure (mmHg) 126.8 ± 5.2 133.8 ± 8.0 0.068
Diastolic blood pressure (mmHg) 82.6 ± 7.1 84.2 ± 6.9 0.902
NEFAs (µmol/L) 387 ± 42 433 ± 45 0.767
Triglycerides (mmol/L) 0.53 ± 0.17 1.29 ± 0.16 0.794
Total Cholesterol (mmol/L) 4.4 ± 0.4 5.2 ± 0.5 0.339
LDL-C (mmol/L) 2.41 ± 0.43 3.03 ± 0.32 0.207
HDL-C (mmol/L) 1.59 ± 0.16 1.11 ± 0.11 0.111
Glucose (mmol/L) 4.45 ± 0.49 5.27 ± 0.62 0.317
HbA1c (%) 5.1 ± 0.4 5.2 ± 0.5 0.339
Insulin (pmol/L) 43.9 ± 4.6 105 ± 18.6 <0.001
Data were expressed as % for categorical variables or mean ± SD for normally distributed variables. Values in bold are significant at
p < 0.05. Abbreviations: BMI, body mass index; NEFAs, non-esterified fatty acids; LDL-C, low-density lipoprotein cholesterol; HDL-C,
high-density lipoprotein cholesterol.
3.2. Serum Leptin Level Is Positively Correlated with Oxidized HDL Levels
As shown in Figure 1a, all the obese individuals met the criteria for hyperleptinemia
(over than 40 ng/mL), and compared to participants with a normal weight, their serum
leptin levels were significantly higher (48.97 ± 1.49 ng/mL vs. 5.742 ± 0.09 ng/mL,
p < 0.001). Additionally, participants with obesity showed higher oxidized HDL levels than
those participants with a normal weight (557.0 ± 19.94 ng/mL vs. 45.35 ± 1.61 ng/mL,
p < 0.001, Figure 1b). As depicted in Figure 1c, the serum leptin level was significantly
positively correlated with the oxidized HDL level (r2 0.9888, p < 0.001).
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Figure 1. (a) Serum leptin levels (ng/mL) and (b) oxidized HDL content (ng/mL) in normal-weight
volunteers and obese subjects. (c) Correlation between serum leptin levels and oxidized HDL content.
Values are presented as means ± SD (n = 20).
3.3. Obesity-Associated Hyperleptinemia Reduced Paraoxonase-1 Levels and Activity
The impact of variations in paraoxonase-1 levels and activity on obese individuals
compared to participants with normal weight is shown in Figure 2. There was a significant
decrease in the serum paraoxonase-1 l vels in individuals with obesity-as ociated hyper-
leptin mia and compared to tho participants with a normal weight (3.44± 1.08 ng/mL vs.
9.57 ± 2.89 ng/mL, p < 0.001, Figure 2a). Similarly, participants wit obesity showed lower
serum paraoxonase activity than those participants with a normal weight (89.80± 8.25 mU/mL
vs. 133.73 ± 19.37 mU/mL, p < 0.001, Figure 2b). In order to explore whether differences in
paraoxonase activity were due to leptin levels, we used Pearson’s r-value. Serum paraox-
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onase activity correlated negatively with leptin levels in both normal-weight and obese
individuals (r2 0.9434, p < 0.001).
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Figure 2. Serum paraoxonase-1 (a) levels (ng/mL) and (b) activity (mU/mL) in normal-weight
volunteers and obese subjects. Values are presented as means ± SD (n = 20).
3.4. HDL Isolated from Hyperleptinemic Obese Subjects Increased Pro-Inflammatory Cytokine
Expression in Microglial Cells
To further explore the possible role of obesity-associated hyperleptinemia on HDL
functionality, we analyzed cytokine expression in microglial cells. As shown in Figure 3,
LPS treatment increased the expression of pro-inflammatory cytokines, such as TNF-α
(Figure 3a) and IL-1β (Figure 3b). All the doses of nor al-weight HDL (nwHDL) had a
significantly anti-inflammatory effect in LPS-stimulated BV2 microglial cells. The addition
of leptin into culture edia enhanced the pro-inflammatory effect of LPS and reverted the
anti-inflammatory capacity of normal-weight HDL at the higher dose (800 µg/mL) skewing
to pro-inflammatory dysfuncti nal HDL particle. In line with these results, in absence
of LPS and leptin into the c lture media, the treatment with HDL isolated from obes
(obHDL) subjects had significantly pro-inflammatory effects in gene expression of TNF-α
and IL-1β at all t e oses ass yed in BV2 microglial cells. Regarding anti-inflammatory
IL-10 gene expression (Figure 3c), the mRNA leve s of IL-10 were overrepresented by
nwHDL treatm nt i the presence of LPS and ptin. However, the capacity to increase
IL-10 mRNA levels was diminish d with obHDL treatment.
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Figure 3. Transcriptional activity (A.U.) of (a) TNF-α, (b) IL-6, and (c) IL-10 genes. BV2 microglial
cells were in ubated with LPS (100 ng/mL) and leptin (10 ng/mL) and treated with HDL isol ted
from normal-weight volunteers (nwHDL) or from obese subjects (obHDL) at 250, 500, and 800 µg/mL
during 24 h. Values are presented as means ± SD (n = 6). * p < 0.05 vs. LPS, # p < 0.05 vs. LPS + leptin,
+ p vs. untreated cells.
3.5. HDL Isolated from Hyperleptinemic Obese Subjects Promotes M1 Polarization in
Microglial Cells
In gaining deeper insight into the role of HDL on microglia polarization under the
influence of LPS and leptin, we bserved that nwHDL downregulated the transcriptional
activity of M1 gene markers, CCR7 (Figure 4a) and iNOS (Figure 4b). In contrast, ob-
HDL not only promoted the mRNA levels of CCR7 and iNOS but also promoted the
transcriptional activity in absence of leptin and LPS. Furthermore, the gene expression
of anti-inflammatory M2 phenotypic markers Arg1 (Figure 5a) and Ym1 (Figure 5b) was
analyzed. Moreover, nwHDL upregulated the Arg1 gene expression at 800 µg/mL; how-
ever, at the same dose, in the presence of leptin, nwHDL lost its M2-promoting capacity. In
contrast, at all doses assayed, obHDL downregulated the mRNA levels of Arg1 and Ym1
in BV2 microglial cells.
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Figure 4. Transcriptional activity (A.U.) of (a) CCR7 and (b) iNOS M1 marker genes. BV2 microglial
cells were incubated with LPS (100 ng/mL) and leptin (10 ng/mL) and treated with HDL isolated
from normal-weight volunteers (nwHDL) or from obese subjects (obHDL) at 250, 500, and 800 µg/mL
during 24 h. Values are presented as means ± SD (n = 6). * p < 0.05 vs. LPS, # p < 0.05 vs. LPS + leptin,
+ p vs. untreated cells.
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Figure 5. Transcriptional activity (A.U.) of (a) Arg1 and (b) YM1 M2 marker genes. BV2 microglial
cells were in ubated with LPS (100 ng/mL) and leptin (10 ng/mL) and t eated with HDL isol ted
from normal-weight volunteers (nwHDL) or from obese subjects (obHDL) at 250, 500, and 800 µg/mL
during 24 h. Values are presented as means ± SD (n = 6). * p < 0.05 vs. LPS, + p vs. untreated cells.
4. Discussion
Neuroinflammation is the onset of several neurodegenerative diseases. Microglial
cells develop a key role in the management of inflammation; microglia differentiate into
a wide ra ge of phenotypes, a d the main ones are M1 and M2 phenotypes, pro- nd
anti-inflammatory, r spectively [19,20]. Inflammation is an essential proc ss to ma ain
physiolo ical status; th M1 phenotype is in charge of the immu e response, and the anti-
infla matory ph notype is crucial to recover the tissue and maintain the homeostasis after
inflamm ion. However, differ nt stimulus, s me associated with obesity, could sustain
inflammation over time, and lead to chronic inflammation. Chronic inflammation would
exacerbate the dis ase and contribute to the onset of other ones.
Obesity-associated hyperleptinemia has been described to stimulate microglial if-
ferentiation into M1 phenotype, contributing t neuroinflammation [18]. On the other
hand, HDLs have been found reduce the inflammatory status, even in the central ner-
vous system, because HDLs can cross the BBB [25]. Nevertheless, HDLs could lose their
anti-inflammatory properties after suffering modifications, such as oxidation and glycoxi-
dation [6].
Even though HDLs and leptin have been tested in microglia and other tissues, their
functions have always been analyzed separately. Therefore, it is completely innovative to
test them together in the search of new insights of relationship and cooperation between
HDLs and leptin in the central nervous system. The purpose of this project was to estab-
lish whether HDL and leptin may act as mediators of microglial plasticity and influence
neuroinflammation.
The data obtained revealed an existing relationship between leptin levels and HDL
oxidation: higher leptin levels positively correlate to HDL oxidation. Therefore, hyper-
leptinemia is associated with HDL dysfunction; specifically, this result suggests that obesity-
associated hyperleptinemia worsens HDL functionality. Obesity itself is described to pro-
mote inflammation, and it is associated with insulin and leptin resistance, which contribute
to higher blood insulin and leptin levels. Altogether, these things promote an inflamma-
tory storm that would reduce HDLs’ functionality and antioxidant and anti-inflammatory
properties, contributing to the rise of pro-inflammatory status.
In this present study, we evaluated the role of healthy and oxidized HDLs in combi-
nation with leptin over microglial cells. HDLs derived from normal-weight volunteers
showed higher antioxidant capacity compared to HDLs derived from obese volunteers.
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PON1 activity and quantity was lower in obese-derived HDLs, and this would contribute
to less functional and more oxidized HDLs.
HDLs derived from healthy volunteers induced microglial polarization into M2 pheno-
type, in line with the cytokine expression profile. On the other hand, obese-derived HDLs
did not show anti-inflammatory function; even HDLs increased the pro-inflammatory sta-
tus, because they induced M1 polarization. These results suggest that obese-derived HDLs
could act as pro-inflammatory particles, which is in concordance with the low antioxidant
capacity that obese-derived HDLs showed.
Additionally, when healthy HDLs were in combination with leptin, HDLs were able
to reduce the pro-inflammatory action of leptin, even though it was less efficient than
in leptin absence. Moreover, when the HDL concentration was high, it contributed to
the increase inflammation. It could imply that a high HDL level in combination with a
pro-inflammatory agent, such as leptin, would deplete HDLs from their anti-inflammatory
functions and would become a pro-inflammatory agent.
These results can be due to two main different factors: that leptin acts as a pro-
inflammatory cytokine in microglia and leads to an oxidative microenvironment that
promotes HDL oxidation, or that HDLs in high concentration could easily reverse their
functionality and act in combination with leptin to increase inflammation. What is clear
is that HDLs vary their functionality according to the environment, and inflammation
could reverse HDL’s beneficial properties. Additionally, high HDL levels could worsen the
output of an inflammatory agent. Hence, increasing the HDL level when an inflammatory
disease is ongoing could not be the best approach to reduce the risk; instead, improving
HDL functionality could be a better approach.
HDLs’ relationship with inflammation is clear; however, their role as pro-inflammatory
or anti-inflammatory depends on the environment. For future research, HDLs should be
tested in combination with other pro-inflammatory agents to clarify the mechanism that
changes HDL anti-inflammatory properties in those previously tested as healthy HDLs.
5. Conclusions
In conclusion, these results suggest that HDLs play a relevant role in microglial plas-
ticity and neuroinflammation. Specifically, in physiological conditions, HDLs develop an
anti-inflammatory function that could be reversed by pro-oxidant and pro-inflammatory
microenvironments, such as obesity-associated endotoxemia or hyperleptinemia. Addition-
ally, our results open new opportunities for testing the effect of different pro-inflammatory
agents over HDL functionality.
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